NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
Toronto – January 27, 2021 (CNW) – Canada House Wellness Group (CSE: CHV) (“Canada House” or the “Company”), a fully integrated medical cannabis company, is pleased to announce the launch of Veterans Kush, a cultivar developed specifically for Veterans with PTSD, by its wholly owned subsidiary Abba Medix Corp. (“Abba”). The cultivar is the first released under Abba’s partnership with InPlanta Biotechnology (“InPlanta”) to access their cannabis genetics and is available exclusively to registered Abba patients.
This strain has been seven years in development. Dr. Darryl Hudson, PhD in Molecular Biology and Genetics, worked previously with Canada House Clinics (at the time operating as Marijuana for Trauma), and veteran patients of the clinics to assess the efficacy of various cultivars for treatment of PTSD and related conditions. Based on that research, InPlanta developed this custom cultivar. Veterans Kush is a hybrid of B.C. Rockstar and Master Kush backcrossed to Rockstar to achieve the cannabinoid and terpene profiles that Veterans have reported having success with.
“As a veteran with combat related PTSD and chronic pain, I am very excited about this Veteran specific strain,” said Glen Coyle, Veteran Advocate for Abba and Canada House Clinics. “This is the only strain that I have tried that gave me all the relief I needed. I am so happy for my fellow brothers and sisters who have served to now have access to Veterans Kush.”
“This has been a long seven-year journey from research, cultivar creation and then finding the right LP partner to bring this to market,” added Dr. Hudson, CEO of InPlanta. “From Canada House Clinics’ history of serving Veterans, to the Veteran focus of Abba’s product portfolio, I am pleased that Canada House has brought this custom cultivar to the Veteran community.”
“Marijuana for Trauma was founded with the mission of helping Veterans with PTSD,” added Mike Southwell, co-founder of Marijuana for Trauma (now Canada House Clinics). “We purchased Abba Medix in 2016 so that we could source and bring to market the best medical cannabis for Veterans who are struggling with PTSD, pain, and lack of sleep. Thank you Dr. Hudson for helping our community with your expertise.”
About InPlanta Biotechnology Inc.
InPlanta Biotechnology Inc. is a leading Cannabis Research & Development company based in Lethbridge, Alberta, lead by Dr. Darryl Hudson and Dr. Igor Kovalchuk who recently attracted international attention through work on Cannabis as a potential therapy in the management of COVID-19.
About Canada House Wellness Group
Canada House Wellness Group is the parent company of Abba Medix Corp., a Licensed Producer in Pickering, Ontario that produces high quality medical grade cannabis; IsoCanMed Inc., a Licensed Producer in Louiseville, Québec growing best-in-class indoor cannabis, in its 64,000 sq. ft. production facility employing state-of-the-art vertical, aeroponic production methodologies; Canada House Clinics Inc., with clinics across the country that work directly with primary care teams to provide specialized cannabinoid therapy services to patients suffering from simple and complex medical conditions; and Knalysis Technologies, a provider of fully customizable, cloud-based software that links physician, provider, and patient to data that supports treatment with medical cannabis.
Canada House Wellness Group’s goal is to become the leading cultivator of premium craft cannabis and provider of cannabinoid therapy, targeting the medical cannabis markets globally. Please visit www.canadahouse.ca or the Company’s public filings at www.sedar.com.
For further information, please contact:
Steven Pearce, Vice-President, Legal
Canada House Wellness Group 289-980-3584
Cautionary Statement Regarding Forward-Looking Information. This press release contains forward- looking statements, including statements that relate to, among other things, the Company’s clinic, production and technology businesses, its future plans, the Company’s markets, objectives, goals, strategies, intentions, beliefs, expectations and estimates, and can generally be identified by the use of words such as “may”, “will”, “could”, “should”, “would”, “likely”, “possible”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “plan”, “objective” and “continue” (or the negative thereof) and words and expressions of similar import. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or
implied in such statements. Material assumptions used to develop forward-looking information in this news release include, among other things, the regulations related to cannabis use under the Access to Cannabis for Medical Purposes Regulations and the act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts, passed by the Canadian Federal government, making cannabis and cannabis based edibles, vapes and oils legal for recreational use on October 17, 2018 and October 17, 2019; Company liquidity and capital resources, including the availability of additional capital resources to fund its activities; level of competition; the ability to adapt products and services to the changing market; the ability to attract and retain key executives; and the ability to execute strategic plans. Additional information about material factors that could cause actual results to differ materially from expectations and about material factors or assumptions applied in making forward-looking statements may be found in the Company’s most recent annual and interim Management’s Discussion and Analysis under “Risk and Uncertainties” as well as in other public disclosure documents filed with Canadian securities regulatory authorities. The Company does not undertake any obligation to update publicly or to revise any of the forward-looking statements contained in this document, whether as a result of new information, future events or otherwise, except as required by law.
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.